The new network study is launched to compare the risk of incident cancer between histamine-2 receptor antagonists.
Comparative risk of the incident cancer between histamine-2 receptor antagonists
Abstract: Dietary N-nitrosodimethylamine (NDMA) has been shown to be carcinogenic in animals, however, evidence from population-based studies is inconlusive. The U.S. Food and Drug Administration has issued a statement on ranitidine because they may contain unacceptable levels of NDMA in 2019.
To date, there have been several studies regarding association between NDMA exposure and risk of cancer, however, real-world evidence of cancer risk in relation with ranitidine is scarce. We aim to evaluate the comparative risk of incident cancer in patients exposed to various H2 receptor antagonists (H2RAs).
We will conduct systematic, multinational study to estimate the relative risk of primary outcome (overall cancer except thyroid cancer) and secondary outcomes (overall cancer, 16 types of cancer, and cancer mortality) in ranitidine cohort. We will compare the target cohort with the comparator cohort for the hazards of outcome during the time-at-risk by applying a Cox proportional hazards model after propensity score adjustment.
The package for feasibility test is available at the OHDSI-Studies Repo
You can see the more detailed protocol here.
Currently, We are searching for collaborators to join this network study and to execute feasibility test of this study. Please follow the instruction, and please send me the result from the feasibility test first before running
The current results from feasibility test will be presented at March 3rd OHDSI call.
If you have any question, comments, or suggestion, please let me know.